Skip to main content
. Author manuscript; available in PMC: 2008 Feb 1.
Published in final edited form as: Cardiovasc Res. 2006 Nov 6;73(3):488–496. doi: 10.1016/j.cardiores.2006.11.003

Figure 1. Experimental protocols.

Figure 1

Timing of interventions is shown in relation to ischemia. Ouabain was perfused at 10 μM. The c-Src kinase inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolol[3,4-d]pyrimidine, 2 μM) and the (PKCε) translocation inhibitor peptide (TIP, 5 μM) were given before, during and after ouabain. After ischemia, all hearts were reperfused with standard Krebs-Henseleit solution. * Except for TIP groups.